Charles River Laboratories International, Inc. (CRL)

NYSE • Currently up 0.89 (+0.54%) in today's trading session

1 member of Congress has disclosed 3 trades in Charles River Laboratories International, Inc. (CRL) via STOCK Act filings. The most recent disclosure was a sale by Susie Lee on 8 October 2019. Aggregate disclosed activity totals roughly $8K in purchases and $16K in sales (midpoint estimates from bracketed disclosure amounts).

Charles River Laboratories International, Inc. is currently trading at $164.73, positioned at 44% of its 52-week range ($113.89 – $228.88).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$164.73
24h Change
+0.89 (+0.54%)
52 Week Range
$113.89—$228.88
View on NASDAQ

Charles River Laboratories International, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for CRL

Select to highlight on chart
3 transactions
Compliance: 100%
Susie Lee8 Oct 20195 Dec 2019SaleStock$1,001 - $15,000N/A
Susie Lee7 Oct 20195 Dec 2019SaleStock$1,001 - $15,000N/A
Susie Lee29 Aug 201930 Sept 2019PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$8.14B

Volume

192.32K

Beta

1.62

P/E Ratio

-56.86

Fundamentals

EPS

$-2.90

Div. Yield

—

Open

$163.15

Day Range

$161.95 — $165.78

Company Information

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NYSE · USD
Country
US
CEO
James C. Foster
IPO Date
2000-06-23
Website
www.criver.com

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally....

Earnings

Next Report

Q1 2026

7 May

EPS Est.

$1.96

Rev. Est.

$977.5M

Days Until

7

Recent Quarters

Q4 202518 Feb
EPS$2.39
Beat 2.6%
Q3 20255 Nov
EPS$2.43
Beat 4.7%
Q2 20256 Aug
EPS$3.12
Beat 24.8%
Q1 20257 May
EPS$2.34
Beat 13.6%
Q4 202419 Feb
EPS$2.66
Beat 6.4%
Q3 20246 Nov
EPS$2.59
Beat 7.0%
Q2 20247 Aug
EPS$2.80
Beat 17.1%
Q1 20249 May
EPS$2.27
Beat 10.2%
Q4 202314 Feb
EPS$2.46
Beat 2.9%
Q3 20238 Nov
EPS$2.72
Beat 15.7%
Q2 20239 Aug
EPS$2.69
Beat 2.3%
Q1 202311 May
EPS$2.78
Beat 7.3%
Q4 202222 Feb
EPS$2.98
Beat 8.4%
Q3 20222 Nov
EPS$2.63
Beat 4.8%
Q2 20223 Aug
EPS$2.77
Beat 1.5%
Q1 20224 May
EPS$2.75
Beat 1.5%
Q4 202116 Feb
EPS$2.49
Beat 2.5%
Q3 20213 Nov
EPS$2.70
Beat 5.1%
Q2 20214 Aug
EPS$2.61
Beat 9.2%
Q1 20214 May
EPS$2.53
Beat 15.5%
Q4 202017 Feb
EPS$2.39
Beat 13.3%
Q3 202029 Oct
EPS$2.33
Beat 29.4%
Q2 20205 Aug
EPS$1.58
Beat 25.4%
Q1 20207 May
EPS$1.84
Beat 24.3%
Q4 201911 Feb
EPS$2.01
Beat 9.8%
Q3 20196 Nov
EPS$1.69
Beat 3.7%
Q2 201931 Jul
EPS$1.63
Beat 5.2%
Q1 20197 May
EPS$1.40
Beat 1.4%
Q4 201813 Feb
EPS$1.49
Beat 6.4%
Q3 20187 Nov
EPS$1.53
Beat 10.9%
Q2 20188 Aug
EPS$1.62
Beat 11.0%
Q1 201810 May
EPS$1.38
Beat 9.5%
Q4 201713 Feb
EPS$1.40
Beat 11.1%
Q3 20179 Nov
EPS$1.30
Beat 6.6%
Q2 20179 Aug
EPS$1.29
Beat 5.7%
Q1 201710 May
EPS$1.29
Beat 13.2%
Q4 201614 Feb
EPS$1.21
Beat 9.0%
Q3 20162 Nov
EPS$1.18
Beat 3.5%
Q2 20163 Aug
EPS$1.20
Beat 9.1%
Q1 20164 May
EPS$0.98
Beat 8.9%
Q4 201510 Feb
EPS$1.00
Beat 6.4%
Q3 20154 Nov
EPS$1.03
Beat 9.6%
Q2 201530 Jul
EPS$0.96
Miss 1.0%
Q1 201529 Apr
EPS$0.79
Miss 3.7%
Q4 201410 Feb
EPS$0.81
Beat 14.1%
Q3 201429 Oct
EPS$0.86
Beat 7.5%
Q2 20146 Aug
EPS$0.97
Beat 18.3%
Q1 201430 Apr
EPS$0.82
Beat 10.8%
Q4 201311 Feb
EPS$0.73
Beat 7.3%
Q3 201329 Oct
EPS$0.79
Beat 12.9%
Q2 201331 Jul
EPS$0.73
Beat 2.8%
Q1 20131 May
EPS$0.69
Miss 2.8%
Q4 201213 Feb
EPS$0.64
Beat 6.7%
Q3 201230 Oct
EPS$0.65
Beat 4.8%
Q2 20127 Aug
EPS$0.75
Beat 13.6%
Q1 20122 May
EPS$0.70
Beat 7.7%
Q4 201113 Feb
EPS$0.69
Beat 23.2%
Q3 20111 Nov
EPS$0.57
Miss 1.7%
Q2 20112 Aug
EPS$0.70
Beat 16.7%
Q1 20113 May
EPS$0.61
Beat 10.9%
Q4 20108 Feb
EPS$0.60
Beat 22.4%
Q3 20103 Nov
EPS$0.45
Miss 8.2%
Q2 20102 Aug
EPS$0.49
Miss 2.0%
Q1 201026 Apr
EPS$0.45
Miss 4.3%
Q4 20098 Feb
EPS$0.49
Beat 11.4%
Q3 20093 Nov
EPS$0.65
Beat 8.3%
Q2 20094 Aug
EPS$0.66
Beat 13.8%
Q1 20095 May
EPS$0.58
Beat 9.4%
Q4 20089 Feb
EPS$0.59
Beat 7.3%
Q3 20085 Nov
EPS$0.76
Beat 1.3%
Q2 20085 Aug
EPS$0.79
Beat 8.2%
Q1 20086 May
EPS$0.72
Beat 4.3%
Q4 200711 Feb
EPS$0.65
Beat 3.2%
Q3 20075 Nov
EPS$0.69
Beat 11.3%
Q2 20077 Aug
EPS$0.64
Beat 3.2%
Q1 20078 May
EPS$0.64
Beat 4.9%
Q4 200612 Feb
EPS$0.58
Beat 0.0%
Q3 20066 Nov
EPS$0.56
Beat 3.7%
Q2 20068 Aug
EPS$0.57
Beat 7.5%
Q1 20069 May
EPS$0.50
Miss 12.3%
Q4 20058 Feb
EPS$0.59
Beat 3.5%
Q3 200527 Oct
EPS$0.57
Beat 0.0%
Q2 200528 Jul
EPS$0.59
Miss 1.7%
Q1 20053 May
EPS$0.55
Beat 0.0%
Q4 200414 Feb
EPS$0.48
Beat 2.1%
Q3 200428 Oct
EPS$0.51
Beat 4.1%
Q2 200428 Jul
EPS$0.52
Beat 6.1%
Q1 200428 Apr
EPS$0.47
Beat 6.8%
Q4 200310 Feb
EPS$0.42
Beat 10.5%
Q3 200329 Oct
EPS$0.40
Beat 0.0%
Q2 200329 Jul
EPS$0.42
Beat 2.4%
Q1 200330 Apr
EPS$0.41
Beat 2.5%
Q4 20023 Feb
EPS$0.36
Beat 0.0%
Q3 200229 Oct
EPS$0.39
Beat 8.3%
Q2 200230 Jul
EPS$0.36
Beat 12.5%
Q1 20021 May
EPS$0.31
Beat 14.8%
Q4 20016 Feb
EPS$0.24
Beat 0.0%
Q3 200131 Oct
EPS$0.26
Beat 13.0%
Q2 20012 Aug
EPS$0.24
Beat 14.3%
Q1 20014 May
EPS$0.19
Beat 11.8%
Q4 200014 Feb
EPS$0.11
Beat 22.2%
Q3 20001 Nov
EPS$0.12
Beat 50.0%
Q2 20008 Aug
EPS$0.34
Q2 20002 Aug
EPS$0.18
Beat 125.0%

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about CRL

Which members of Congress have traded CRL?
1 member of Congress has disclosed 3 trade in Charles River Laboratories International, Inc. (CRL) under the STOCK Act: Susie Lee.
When was CRL most recently disclosed by Congress?
The most recent CRL disclosure was a sale by Susie Lee on 8 October 2019.
What is the total disclosed congressional trading volume for CRL?
Members of Congress have disclosed approximately $8K in CRL purchases and $16K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in CRL?
This CRL page updates as soon as new STOCK Act disclosures are filed for Charles River Laboratories International, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi TrackerJoin our Discord
PoliticiansPortfoliosPricingLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.